The role of two important tumour suppressor genes, p16 and p53, was evaluated in cartilaginous tumour tissues. Genomic DNA from 22 chondrosarcomas, 5 benign chondroid tumours, 1 sample of reactive proliferative cartilage and 2 samples of normal cartilage were analysed using polymerase chain reaction
Changes in p14ARF do not play a primary role in human chondrosarcoma tissues
β Scribed by Julia Asp; Camilla Brantsing; Maria Serena Benassi; Sven Inerot; Luca Sangiorgi; Piero Picci; Anders Lindahl
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 106 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.1398
No coin nor oath required. For personal study only.
β¦ Synopsis
The locus encoding the tumor suppressor p16 has been found to code for a second, different protein. This protein, p14(ARF), has been shown to protect p53 from degradation. Like p16, its gene is often altered in different cancers. In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. One chondrosarcoma was found to have exon 1 beta homozygously deleted, but neither mutations nor methylations were found in any of the chondrosarcomas. This indicates that genetic changes of p14(ARF) are a rare event in chondrosarcoma.
π SIMILAR VOLUMES
The loss of full-length dystrophin from skeletal muscle leads to the clinical features of Duchenne muscular dystrophy. Both Dp71, a Cterminal dystrophin isoform, and the dystrophin-related protein, utrophin, are present at high levels in many nonmuscle tissues. To investigate the roles of these prot
β€-catenin has been identified as an oncogene. Phosphorylation of sites encoded by exon 3 of the β€-catenin gene facilitates degradation of this protein by the adenomatous polyposis coli (apc) gene product. Mutations in these sites or inactivation of apc lead to stabilization of β€-catenin, which then